echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere Pharmaceuticals declares new drug for Alzheimer's disease

    Simcere Pharmaceuticals declares new drug for Alzheimer's disease

    • Last Update: 2021-12-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 14, CDE's official website showed that Simcere/Vivoryon Therapeutics' new Alzheimer's disease drug PQ912 was reported for the first time in China


    From: CDE official website

    Varoglutamstat (PQ912) is an oral small molecule inhibitor of glutamyl peptide cyclase (QPCT)


    Varoglutamstat plays a role in the early pathogenesis of the disease by preventing the formation of this toxic variant, so it has the potential to prevent neuronal damage


    Neurotoxic amyloid N3pE can trigger AD-related pathological pathways, including Aβ oligomer formation, neuroinflammation, and tau-mediated neurotoxicity

    The two products introduced by Simcere during the same period both target N3pE


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.